Sorry, you need to enable JavaScript to visit this website.
Skip to main content


Janssen Diagnostics Leadership Team

Janssen Diagnostics Leadership


Precision Medicine

Precision Medicine

Donna Williams, Family
Donna Williams, Family

Werner Verbiest is Global Head of Janssen Diagnostics, which was formed from the legacy organizations Virco (Infectious Diseases), Veridex (Oncology) and the Johnson & Johnson Companion Diagnostics Center of Excellence. Janssen Diagnostics focuses on personalized medicine within Janssen, incorporating therapeutic, diagnostic and real world data/health information technology solutions to improve patient outcomes.

Werner joined the Johnson & Johnson Family of Companies in 2002 following the acquisition of Tibotec-Virco. Before joining, he was active since 1992 in HIV drug development and hepatitis B therapeutic vaccine development in the International Clinical Research & Development group of the Janssen Research Foundation.  He was one of the first employees of Virco in 1997 and had an instrumental role in Virco’s growth as Project and Business Development Director (1998), Managing Director (Virco Ireland, Ltd, 1999), Vice President of New Products Marketing and Pharma Business (2001) and General Manager from 2004 until its integration into Janssen Diagnostics.

Werner has been continually active in all phases of HIV clinical trial strategy and implementation, biomarker development (collaborative surrogate marker validation working groups with the United States Food andl Drug Administration and the European Medicines Agency), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.

In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach both within and outside of Johnson & Johnson, including several board seats in different precision medicine and diagnostic organizations, including the European Personalised Medicine Association (EPEMED) and AdvaMedDx.

Werner Verbiest

Global Head, Janssen Diagnostics

Jorge Villacian, M.D. joined the Johnson & Johnson Family of Companies as Director of Medical Affairs for Virco in Belgium in 2006. He holds an M.D. from Universidad Anahuac, Mexico City and specialized in Internal Medicine at the Mount Sinai Medical Center in Miami, Florida, and in Infectious Diseases at the Mayo Clinic in Rochester, New York. Jorge worked in the public health and hospital infectious diseases fields in the South Pacific and in Singapore developing clinical and translational research capabilities.  He also held a clinical teaching appointment with the National University of Singapore. Prior to joining Johnson & Johnson, Jorge led the clinical development of a protease inhibitor for the treatment of resistant HIV in Europe, Asia and Latin America with Boehringer Ingelheim in a program culminating with the approval of the drug for the treatment of multi-resistant HIV. He has presented and published extensively on topics related to infectious diseases and, in particular, to HIV.

Jorge Villacian, M.D.

Chief Medical Officer, Janssen Diagnostics

Peter Hoehn, J.D. leads the Janssen Co Diagnostic Commercial Strategy Group and serves on Janssen Diagnostics’ Senior Leadership team. Peter’s team is responsible for setting overall business objectives and strategic priorities for diagnostic solutions areas across Janssen, which includes health economic, reimbursement and pricing strategies across the Janssen portfolio of diagnostic projects.

Peter obtained a B.A. in Government and Economics from the College of William and Mary in Williamsburg, Virginia, and a J.D. from New York University in New York City. Peter started his career as a corporate lawyer and entered the pharmaceutical industry as an attorney for Bristol-Myers Squibb. He then moved in to various strategy, marketing and sales management roles, primarily in the oncology and cardiovascular areas.

Peter joined Johnson & Johnson in 2003 in the Pharmaceuticals Group Strategic Marketing organization as a Global Commercial Leader, and in 2005 was promoted to Global Marketing Leader – Neurology, where he had global commercial responsibility for in-line neurology products as well as products in late-stage development. In 2008 Peter joined the Ortho Clinical Diagnostics (OCD) organization as Global Marketing Leader and was promoted to Vice President for Worldwide Marketing and Strategic Marketing in 2010. In this role, Peter and his team set overall marketing strategies and plans for the worldwide clinical laboratory diagnostics business, defined and managed the pipeline of new products, and identified and assessed new growth opportunities. Peter was also an original team member of the Janssen Companion Diagnostics Center of Excellence while at OCD.

Peter Hoehn, J.D.

Co Diagnostics Commercial Strategy Leader, Janssen Global Commercial Strategy Organization

After completing his Masters in Medical Biology in Utrecht, Netherlands and an M.B.A. at the Rotterdam School of Management, Netherlands, Daap Kooij started his professional career at Organon Teknika NV in 1997 in a global marketing capacity in hemostasis diagnostics. Over time he adopted new marketing- and business-related roles with increasing levels of responsibility, and in his last assignment he was the Commercial Director for the global molecular diagnostics business line. In 2000, Daap joined Virco, a Belgium-based biotech pioneer, as Director Business Development with an initial assignment in oncology diagnostics and later focusing on the HIV resistance business. In 2002 Virco was acquired by Johnson & Johnson. He became Vice President, International Marketing and Sales. In 2008, his business focus extended to include Virco’s diagnostics in viral hepatitis. In 2009, Virco’s business diversified further to include Health Information Technology (Health IT) platform development, and as Global Business Leader Daap was assigned responsibility for Infectious Diseases Diagnostics and Health IT. Today Daap is responsible for Diagnostics Integration in support of our Global Public Health, Disease Prevention/Interception and Microbiome related diagnostic initiatives.

Daap Kooij

Global Business Leader – Diagnostics Integration, Janssen Diagnostics

Carmen Damink is Director of Quality, Janssen Diagnostics. In this role, she provides strategic direction and leadership for New Product Development Quality as well as the management of global quality processes as Director, Janssen Digital and Diagnostics Quality, BioResearch Quality and Compliance, Janssen. She is designated as the Quality Management Representative for Janssen Diagnostics-Janssen Pharmaceuticals NV.

Carmen has more than 29 years of experience in quality and research & development (R&D) in the health care and food industries. She also is a graduate of the Johnson & Johnson Executive Quality Leadership Development program (EQLD). Since 2006, she has been an engaged mentor at programs such as the J&J Diversity & Inclusion ‘Sofia Program’ to support the development of Women Leaders.

Prior to joining Janssen Diagnostics, Carmen fulfilled several Quality-related functions within the Pharmaceutical sector of Johnson & Johnson, as well as in Large Molecules and Small Molecules. Prior to joining the company, she held managerial roles in Quality in an in vitro diagnostic company (Innogenetics) and a food company (Kraft Jacobs Suchard-Côte d’Or).  Carmen began her career as a Research Associate at Centocor Europe in Leiden (The Netherlands).

Carmen holds a Master’s Degree in Biological Science from the University of Utrecht in The Netherlands, specializing in Medical Biological Science (Immunology, Molecular Biology and Microbiology) and is also a Certified Quality Assurance Auditor.

Carmen Damink

Director of Quality, Janssen Diagnostics

Debra J. Rasmussen supports regulatory affairs for Janssen Diagnostics. In this role, she is responsible for development of regulatory strategy, policy and registration of the in vitro diagnostic devices associated with Johnson & Johnson drug development and commercialization. For Janssen, both companion and complementary diagnostics and mobile medical applications regulatory strategy and expertise are driven by the Global Regulatory Affairs Diagnostics group.

Deb’s regulatory and quality career has spanned both large and small companies and both United States and global programs. She has been in diagnostics for more than 25 years and gained her experience working at Bio-Rad Laboratories, Roche Molecular Systems, Chiron Corporation (now Novartis), Applied Imaging Corporation and Visible Genetics. She holds an M.B.A. from St. Mary’s College in Maryland and a Bachelor of Science degree in Bacteriology/Immunology from the University of California, Berkeley.

Debra J. Rasmussen

Global Regulatory Affairs Senior Director, Janssen Pharmaceuticals

In this role, Paul Kildal-Brandt leads the Business Alliance and Business Development functions for companion and complementary diagnostic products from inception through commercialization.

Paul has 27 years of experience in the diagnostic and pharmaceutical industries in roles spanning many business functions. Prior to joining Janssen in 2011, Paul was Worldwide Vice President of Franchise Development for Ortho-Clinical Diagnostics.

As the leader of Franchise Development, Paul had global responsibility for business development activities including in-licensing, out-licensing, acquisition, divestiture and strategic partnership efforts. From 2005 until July 2007, Paul led the Worldwide Immunohematology (IH) franchise at Ortho-Clinical Diagnostics, where he worked closely with the regional sales teams and had profit and loss responsibility for this $400-million line of business.

Paul began his career in 1988 as an engineer in Operations and then progressed through various Research & Development positions before making a transition to Sales and then Global Marketing. Paul has a Master’s degree in Mathematics from the University of Minnesota in Minneapolis and is a Johnson & Johnson Process Excellence Black Belt.

Paul Kildal-Brandt

Senior Director – Diagnostic Business Development, Janssen Business Development

Carol Leland, LL.M. is the lead attorney supporting the Global HIV business as well as the Global Public Health Organization. On joining Johnson & Johnson from private practice in 2005, Carol supported the Virco business and now is the lead attorney for the Jansen Diagnostics business. Carol works with other members of the law department to ensure that Janssen Diagnostics has the required legal support for its global projects and is adequately informed of the significant legal issues arising in our global business environment.

Carol holds a Master’s degree in European Studies, an LL.M. from University College Dublin, Ireland, a Barrister at Laws Degree from the Honorable Society of Kings Inns, also in Dublin, and an Oxford Diploma in Organizational Leadership from Oxford University, England. Prior to joining Johnson & Johnson, Carol worked in private practice as a barrister and then in an international law firm specializing in healthcare law.

Carol Leland, LL.M.

Assistant General Counsel and a member of the Johnson & Johnson Law Department

Susan Mallows leads project management and decision support for Janssen Diagnostics, with responsibility across the full portfolio of complementary and companion diagnostics under development within our organization. 

Susan joined Johnson & Johnson in 2000. She also leads the Regulatory Program Management department which supports Janssen Regulatory Affairs and is the Decision Support Leader for the Janssen R&D Development Committee.

She has provided leadership to development teams as a Program Management Leader across multiple therapeutic areas and acted as Decision Support Leader for the Metabolic Disease Area Stronghold.  

Prior to working at Johnson & Johnson, Susan worked for a number of years at Novartis in Research and Development including roles in Clinical Development, Regulatory Affairs and Toxicology.

She earned her undergraduate degree in Biology from Kean University in New Jersey and her Master’s in Business Administration from Columbia University in New York. She is credentialed as a Project Management Professional by the Project Management Institute.

Susan Mallows

Senior Director, Regulatory and Janssen Diagnostics Project Management

Andrew Ritterman (Andy) joined the Janssen Diagnostics Senior Leadership Team in February 2017 as Human Resources Leader. He brings more than five years of human resources experience to the role. Prior to joining Janssen, Andy was previously with Rothman Institute Orthopedics, based in Philadelphia, Pennsylvania.

Andy graduated with a Bachelor’s in Business Administration from the University of Pittsburgh (Pennsylvania). He currently holds his Professional in Human Resources® (PHR) and Society for Human Resource Management, Certified Professional (SHRM-CP) certificates.

Andy Ritterman

Human Resources Leader,
Janssen Research & Development

Matt Mailman, Ph.D. is the R&D IT Business Technology Leader accountable for coordinating digital health, advanced analytics and experimental execution technology to enable the Janssen Diagnostics strategy.

Before joining R&D IT, Matt served as Director and Solution Development Team Leader in the Janssen Neuroscience therapeutic area. During his six years in Janssen R&D, he developed companion and complementary diagnostics as well as digital solutions aimed at differentiating and advancing the Alzheimer’s disease and schizophrenia portfolio.

Prior to joining Janssen, Matt was Manager of Tailored Therapeutics IT and Senior Biomedical Informatics Scientist at Eli Lilly where he built informatics platforms that support the formulation of pharmacogenomic precision medicine hypotheses. Before that, he led the development of the widely utilized Database of Genotype and Phenotype (dbGaP) at the National Center for Biotechnology Information (NIH).

Matt received his Ph.D. in molecular pathology from the Ohio State University, M.S in oncology from the University of Wisconsin at Madison and M.S. in bioinformatics during his postdoctoral fellowship at the University of Pennsylvania, Philadelphia, Pennsylvania.

Matt Mailman, Ph.D.

R&D IT Business Technology Leader

Yiu-Lian Fong is the Global Head for Diagnostic Innovation, Research & Early Development, and Lab Operation for Janssen Diagnostics. In this role, Yiu-Lian is responsible for identifying and assessing innovative, enabling and disruptive diagnostic biomarkers, technologies and solutions, as well as for companion & complementary diagnostic and clinical trial assay development, validation and execution in certified Clinical Laboratory Improvement Amendments (CLIA) Lab to help facilitate clinical development, drive precision medicine and advance J&J’s pipelines.

Prior to joining the Johnson & Johnson family, Yiu-Lian was the Divisional Vice President at Abbott responsible for Abbott Molecular R&D managing more than 150 full-time employees, including Assay Development, System Engineering, System Integration, Scientific Affair and Project Management. Previously, she served as the Executive Director for Molecular Diagnostics and Companion Diagnostics Development at Novartis managing more than 80 full-time employees and was responsible for diagnostic (Dx) platform technologies and strategies for all companion and complementary Dx assay development, and bridging with Clinical Trial Assays. She served Novartis/Chiron for total of 18 years with various leadership roles including therapeutic drug & vaccine development, as well as molecular-based (polymerase chain reaction and sequencing) and protein-based biomarker and diagnostic development.

Yiu-Lian has track record of successful product development and regulatory approvals for drug, blood screening and in-vitro diagnostics.

Yiu-Lian earned her Ph.D. in Molecular Physiology and Biophysics from Vanderbilt University and was post graduate fellow at Dr. Daniel Nathan’s Lab at the Johns Hopkins University. She also received her Master in Business Administration from the University of Massachusetts, Amherst.

Yiu-Lian Fong, Ph.D.

Global Head for Diagnostic Innovation, Research & Early Development, and Lab Operation